Business Context and Reporting Period
This Form 8-K, dated October 13, 2015, reports the completion of a merger by Atricure, Inc. ("Atricure") with nContact Surgical, Inc. ("nContact"). The transaction was consummated on October 13, 2015, pursuant to a Merger Agreement dated October 4, 2015. nContact was merged into a wholly-owned subsidiary of Atricure, with the subsidiary surviving as a subsidiary of Atricure.
Key Financial Metrics and Transaction Details
This filing is a current report regarding a corporate event and does not contain standard financial statements (revenue, profit, cash flow, margins, or debt) for the reporting period. The primary financial metric disclosed relates to the consideration paid for the acquisition:
- Equity Issuance: Atricure issued an aggregate of 3,757,028 shares of common stock ($0.001 par value) to nContact shareholders.
- Escrow Arrangement: Of the shares issued, 304,876 were deposited into an escrow account to cover potential post-closing claims.
- Regulatory Status: The shares were offered and sold in a private offering to accredited investors under Section 4(2) of the Securities Act of 1933.
Pro forma financial information and financial statements of the acquired business are not included in this filing; they are scheduled to be filed via amendment within 71 days of this report.
Material Changes
The material change reported is the acquisition of nContact Surgical, Inc. This transaction expands Atricure's portfolio and operations. No other material changes to financial position or operations are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing includes a "Forward-Looking Statements" section outlining expectations and risks associated with the merger and future operations:
- Outlook: Management anticipates revenue growth from nContact, achievement of clinical development milestones, and potential synergies and cost savings from the integration.
- Risks and Uncertainties:
- Market acceptance of Atricure's and nContact's products.
- Ability to develop, market, and obtain regulatory clearances for new products.
- Reimbursement challenges for procedures utilizing the products.
- Integration risks, including operational disruption and employee retention.
- Failure of the acquired company to achieve its plans and objectives.
- General risks including competition, reliance on third-party manufacturers, and litigation.
Atricure explicitly states it does not guarantee forward-looking statements and undertakes no obligation to update them.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement (filed as Exhibit 2.1 to the October 5, 2015, 8-K) for details on valuation and conditions.
- Monitor the upcoming amendment to this 8-K (due within 71 days) for the required pro forma financial information and nContact's financial statements.
- Review the press release (Exhibit 99.1) for management's specific commentary on the strategic rationale and immediate impact.
- Assess the impact of the 304,876 shares held in escrow on the total dilution to existing shareholders.
- Track future filings for updates on the integration progress and realization of anticipated synergies.